Span Divergent Limited - Outcome of Board Meeting held on November 10, 2025
Awaiting price reaction for this filing.
Span Divergent's board approved unaudited Q2/H1 FY26 results, where standalone PAT fell sharply to Rs. 12.01 lakhs (vs Rs. 47.26 lakhs YoY) and consolidated reported a loss of Rs. 18.77 lakhs for the quarter, with negative consolidated net worth of Rs. 919.92 lakhs. Two directors stepped down: Independent Director Mr. Nirav Jogani (due to other professional commitments) and founder-era Non-Executive Director Dr. Pradipkumar Desai (citing advancing age), who was given the honorary title of Chairman Emeritus. Mr. Dharmesh Vinodbhai Desai was appointed as an Additional Non-Executive Independent Director for five years. The board also approved the sale of a 99% stake in dormant subsidiary Span Diagnostics LLP to promoter-group members for Rs. 99,000, reconstitution of three board committees, and exploration of fund-raising options including a possible FPO or preferential allotment. Additionally, the board approved reviving operations of Aranya Agri Biotech LLP, whose assets have been reclassified as PPE.
Mixed-to-cautious: weak consolidated financials with deeply negative net worth and loss-making subsidiaries may pressure the stock, while the possible FPO/preferential allotment introduces dilution risk for existing shareholders. However, the leadership transition is orderly, with a new independent director bringing 20+ years of industry experience and the founder retained in an advisory Chairman Emeritus role.